Skip to main content

Program Director

Amy Finkelstein Profile (1).jpg

Amy Finkelstein is the John and Jennie S. MacDonald Professor of Economics at the Massachusetts Institute of Technology and the co-founder and Co-Scientific Director of the Jameel Poverty Action Lab-North America.  Her research interests focus on public finance and health economics, particularly market failures and government intervention in insurance and health care markets. She has been an NBER affiliate since 2001.

Featured Program Content

The figure is a density plot titled, "Length of Clinical Development: Drugs with vs without Breakthrough Designation."  The y-axis, which plots density, ranges from 0 to 0.0006, and the x-axis, which represents the number of days between the start of Phase III trials and drug application submission, ranges from 0 to 8,000.   Clinical development duration is shorter for drugs with the breakthrough designation.   Source: Researchers’ calculations using data from the FDA
  • Article
In 2012, to address rising concerns about the time required to develop vital medications, Congress passed legislation creating the Breakthrough Therapy...
Working Paper Figure w29809
  • Article
Over the last two decades, the US hospital sector has experienced significant consolidation, with over 1,600 mergers among the nation’s 6,000 hospitals....
Working Paper Figure w29765
  • Article
Millions of elderly veterans are “dually eligible” to receive hospital care in two distinct settings: at public facilities funded by the US Department of...
Abstracts of New NBER Working Papers Delivered to Your Inbox
Explore Ongoing NBER Research Projects